Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAYHIT1: Ianalumab plus first-line corticosteroids in primary immune thrombocytopenia
2022-001672-34Phase 3Active
- Sponsor
- Novartis
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in immune thrombocytopenia (ITP) comparing Ianalumab plus first-line corticosteroids with Placebo plus first-line corticosteroids (2 arms). Primary endpoint: Time to treatment failure. Started Oct 2022; status: active.
02
Drugs
ianalumab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2022-001672-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001672-34.